Coagulopathy and disseminated intravascular coagulation (DIC) is one of the complications of the corona virus disease 2019 (Covid-19) that can lead to death. Several studies have shown that anticoagulants provide good clinical outcomes in Covid-19 patients, especially in severe cases. This case emphasizes the administration of low molecular weight heparin (LMWH) to prevent venous thromboembolism (VTE) in severe case of Covid-19.
___
1. Ministry of Health of the Republic of Indonesia. Covid-19 update. Published March 8, 2020. Accessed May 8, 2020. https://infeksiemerging.kemkes.go.id/
2. World health Organization. Coronavirus disease (COVID-19) Pandemic. Published March 8, 2020. Accessed May 8, 2020. https://www.who.int/emergencies/diseases/n ovel-coronavirus-2019
3. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315: 801-810.
4. Levi M, van der Poll T. Coagulation and sepsis. Thrombosis research 2017; 149: 38-44.
5. Iba T, Levy JH, Warkentin TE, Thachil J, van der Poll T, Levi M, Scientific and Standardization Committee on DIC, and the Scientific and Standardization Committee on Perioperative and Critical Care of the International Society on Thrombosis and Haemostasis. Diagnosis and management of sepsis‐induced coagulopathy and disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis 2019; 17: 1989- 1994.
6. Iba T, Di Nisio M, Levy JH, Kitamura N, Thachil J. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ open 2017; 7: e017046.
7. Luo W, Yu H, Gou J, Li X, Sun Y, Li J, Liu L. Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19). Pathology & Pathobiology 2020; 2020020407.
8. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of Thrombosis and Haemostasis 2020; 18: 1094-1099.
9. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020. World Health Organization 2020.
10. Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. Journal of Thrombosis and Haemostasis 2010; 8: 2450-2457.
11. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 2020; 395: 507-513.
12. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: aretrospective cohort study. The Lancet 2020; 395: 1054-1062.
13. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020; 323: 1061-1069.
14. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020; 2020006000.
15. Delabranche X, Helms J, Meziani F. Immunohaemostasis: a new view on haemostasis during sepsis. Annals of intensive care 2017; 7: 117.
16. Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood 2019; 133: 906-918.
17. Zakai NA, McClure LA. Racial differences in venous thromboembolism. Journal of Thrombosis and Haemostasis 2011; 9: 1877- 1882.
18. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? European Heart Journal 2020; 41: 1858-1858.
19. Xie Y, Wang X, Yang P, Zhang S. COVID-19 Complicated by Acute Pulmonary Embolism. Radiology: Cardiothoracic Imaging 2020; 2: e200067.